News Daily News Fewer MACE in Diabetic Patients Taking SGLT2 Inhibitors vs DPP-4 Inhibitors Shelley Wood September 30, 2020
News Daily News VERTIS CV: Ertugliflozin Meets Noninferiority Endpoint but Misses Other Marks Michael O'Riordan September 24, 2020
News Conference News ESC 2020 EMPEROR-Reduced: Empagliflozin Cuts Hospitalizations, CV Mortality in HFrEF Michael O'Riordan August 28, 2020
News Daily News New Guidance on Use of Diabetes Drugs for CVD Risk Reduction: ACC Experts Michael O'Riordan August 06, 2020
News Opinion Editor's Corner TCTMD’s Top 10 Most Popular Stories for July 2020 Shelley Wood July 31, 2020
News Daily News LEADER Analysis Reassures on Liraglutide in Diabetic Patients With Heart Failure Shelley Wood March 10, 2020
News Daily News Trials of New Cancer Drugs Failing to Address Potential CV Risks Todd Neale February 10, 2020
News Conference News ACC 2019 New DECLARE-TIMI 58 Data Shine a Light on Diabetes Patients Most Likely to Benefit From Dapagliflozin Shelley Wood March 26, 2019
News Conference News AHA 2018 DECLARE-TIMI 58 Supports HF Benefit of SGLT2 Inhibitors Todd Neale November 10, 2018
News Conference News AHA 2018 AHA 2018: New Cholesterol Guidelines, Fish Oil, Diabetes Meds, and Inflammation Blow Into the Windy City Shelley Wood November 05, 2018
News Daily News Do PVADs and IABPs Offer Similar Survival in High-Risk PCI or Cardiogenic Shock? Caitlin E. Cox July 30, 2018
News Daily News SGLT2 Inhibitors Work in Type 2 Diabetes Across Levels of CV Risk, Renal Function Todd Neale July 02, 2018
News Opinion Editor's Corner ESC 2017 ESC 2017: In Tragedy’s Wake, Cardiology’s Biggest Congress Forges On Shelley Wood August 18, 2017
News Industry News Resverlogix Officially Attains Phase 3 Status with a European Regulatory Authority June 22, 2015
News Daily News Shock-Wave Preconditioning Boosts Cell Therapy for Chronic Heart Failure L.A. McKeown April 19, 2013
News Daily News El Preacondicionamiento con Ondas de Choque Potencia la Terapia Celular contra la Insuficiencia Cardíaca Crónica L.A. McKeown April 19, 2013